Sandoz and Biocon Biologics sign distribution deal for key immunology drug

Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd and a prominent player in the global biosimilars market, has entered into a pivotal Distribution Agreement with Sandoz. This agreement confers exclusive rights to Sandoz for the promotion, sale, and distribution of the Adalimumab biosimilar for subcutaneous injection [FKB] in Japan. This move represents a significant strategic step in expanding Biocon Biologics‘ global footprint, particularly in the Japanese pharmaceutical market.

As of December 15, 2023, Viatris, the former marketer of Adalimumab BS, has ceased its marketing and promotional activities but will continue to support the transition until Sandoz assumes full responsibility for the product from February 15, 2024. This transition is a part of Biocon Biologics’ larger strategy, having recently acquired the global biosimilars portfolio from Viatris, which includes Adalimumab.

The Adalimumab biosimilar, developed by Fujifilm Kyowa Kirin Biologics Co. Ltd., has received an exclusive global marketing license by an affiliate of Biocon Biologics Ltd. This biosimilar, a counterpart to the brand-name drug Humira, is indicated for various immune-related diseases, such as rheumatoid arthritis, psoriasis vulgaris, ankylosing spondylitis, Crohn’s disease, and ulcerative colitis.

Biocon Biologics Secures Exclusive Distribution Rights for Adalimumab Biosimilar in Japan

Sandoz, dedicated to strengthening its product pipeline, views this distribution agreement as a key component of its strategy to bolster its immunology and biosimilar portfolio. Meanwhile, Biocon Biologics recently celebrated the early completion of integrating Viatris’ biosimilars business, which spans 120 countries. With a robust pipeline of 20 assets covering diabetology, oncology, immunology, and ophthalmology, Biocon Biologics is significantly impacting the global healthcare landscape.

This agreement marks a major milestone for both Biocon Biologics and Sandoz, highlighting their commitment to providing sustainable and affordable access to biologic medicines. Sandoz, with its history of launching the first biosimilar in Europe in 2006, is set to be a trusted partner in delivering high-quality medicines in Japan, aiming to enhance the sustainability of the Japanese healthcare system.